WO2007104474A1 - Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid - Google Patents

Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid Download PDF

Info

Publication number
WO2007104474A1
WO2007104474A1 PCT/EP2007/002029 EP2007002029W WO2007104474A1 WO 2007104474 A1 WO2007104474 A1 WO 2007104474A1 EP 2007002029 W EP2007002029 W EP 2007002029W WO 2007104474 A1 WO2007104474 A1 WO 2007104474A1
Authority
WO
WIPO (PCT)
Prior art keywords
malic acid
terbinafine
salt
topical
amount
Prior art date
Application number
PCT/EP2007/002029
Other languages
French (fr)
Inventor
Michel Steiger
Catherine Larnier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604934A external-priority patent/GB0604934D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2007104474A1 publication Critical patent/WO2007104474A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the invention relates to topical pharmaceutical compositions with antimycotic activity.
  • topical terbinafine products which are able to cure e.g. athlete's foot by just a single administration ("one shot use", Lamisil Once®).
  • a topical terbinafine product that allowed the active substance, terbinafine, more efficiently and rapidly to reach the deepest layer of stratum corneum (where the pathologic fungi usually are located in moccasin pedis) than currently available products would be highly desirable.
  • topical compositions comprising antifungals and hydroxydicarboxylic acids, among them malic acid mentioned, are disclosed which exhibit an enhanced therapeutic activity of the antifungal and which make the antifungal better bioavailable "to the target sites in the skin”.
  • salts of terbinafine with malic acid which have beneficial pharmacokinetic and favorable formulation properties.
  • Malic acid (2) is HOOC-CH 2 -CH(OH)-COOH and can be present in racemic or enantiomeric form, preferably in racemic DL( ⁇ )- or in enantiomeric L(-)-form, especially in enantiomeric L(-)-form.
  • Salts of terbinafine with malic acid (1) can either be in hydrogen malate (mono-salt) or malate (di-salt) form, preferred is hydrogen malate.
  • malic acid incorporated in terbinafine salts (1) the same preferences are valid as indicated for malic acid (2) above.
  • terbinafine DL( ⁇ )-hydrogen malate (1 ) always with DL( ⁇ )- malic acid (2).
  • the topical pharmaceutical compositions according to the invention comprise the salts of terbinafine with malic acid (1) in an amount of from 0.1 up to 10 wt%, especially of from 0.5 up to 5 wt%, more especially of from 0.5 up to 3 wt% and in particular of from 0.5 up to 1.5 wt%, of the total composition.
  • the topical pharmaceutical compositions according to the invention comprise malic acid (2) in an amount of from 0.5 up to 30 wt%, especially of from 0.5 up to 20 wt% and in particular of from 1 up to 10 wt%, of the total composition.
  • topically acceptable excipients used largely depend on the kind of topical composition involved (see below).
  • the latter include e.g. aqueous phases, oily phases, emulsions or the typical components of a film-forming solution known per se.
  • topical compositions of the invention allow better and deeper penetration of the actice substance, terbinafine, to the deep sites where the pathologic fungi are usually located in many dermatomycoses, e.g. in moccasin pedis.
  • compositions of the invention are compared with a commercially available topical antifungal.
  • the dosing and frequency of treatment is the same in both groups.
  • the topically administered pharmaceutical compositions according to the invention comprise the terbinafine salt with malic acid (1) in a pharmacologically effective amount.
  • topical pharmaceutical compositions e.g. in the form of emulsion-gels, gels or creams
  • Film-forming solutions may be applied, for example, once only, or once daily.
  • the invention further relates to the use of (1 ) a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition (for the manufacture of a pharmaceutical composition adapted to topical administration, which pharmaceutical composition is intended) for the prevention and treatment of fungal infections.
  • the invention relates to a method of preventing and treating fungal infections which comprises administering to a mammal in need thereof a topical composition which comprises (1) a therapeutically effective amount of a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition.
  • compositions suitable for topical administration are e.g. emulsion-gels, gels, foam gels, creams, lotions, solutions, microemulsions, ointments, fatty ointments, shampoos, pastes, foams, tinctures, film-forming solutions and nail lacquers (varnishes); preferred are emulsion-gels, gels, foam gels, creams, lotions, solutions, shampoos, film-forming solutions and nail lacquers.
  • the manufacture and composition of such topical pharmaceutical compositions are known in the art (see e.g. WO 98/00168 A1, pages 8-15 or US patent 5,681 ,849).
  • the concept of film-forming solutions is known in the art and e.g. disclosed in WO 98/23291 A1.
  • the concept of nail lacquers (varnishes) is known in the art and e.g. disclosed in EP 515,312 A2.
  • creams oil-in-water emulsions
  • emulsion-gels gels and film-forming solutions, in particular creams.
  • Example 1 A cream comprising 1.46% terbinafine DL( ⁇ )-hydrogen malate and 1.0% DL( ⁇ )-malic acid is manufactured as follows.
  • a and B are dispersed in K and heated to 75°C.
  • Example 2 A cream comprising 1.46% terbinafine L(-)-hydrogen malate and
  • L(-)-malic acid 0.5% is manufactured as described in Example 1 , with using 0.5g of L(-)-malic acid (B) and 0.3g of (J).
  • Example 3 A cream comprising 1.46% terbinafine DL( ⁇ )-hydrogen malate and 2.0% DL( ⁇ )-malic acid is manufactured as described in Example 1 , with using 2.Og of DL( ⁇ )-malic acid (B) and 1.1g of (J).
  • Example 4 A cream comprising 1.46% terbinafine L(-)-hydrogen malate and
  • L(-)-malic acid is manufactured as described in Example 1, with using 5.Og of L(-)-malic acid (B) and 2.5g of (J).
  • Example 5 A cream comprising 1.46% terbinafine DL( ⁇ )-hydrogen malate and

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to topical pharmaceutical compositions comprising certain terbinafine salts and malic acid. Said compositions exhibit beneficial antimycotic and skin-treating properties.

Description

ANTIFUNGAL COMPOSITIONS COMPRISING (1) A SALT OF TERBINAFINE WITH MALIC ACID AND (2) MALIC ACID
The invention relates to topical pharmaceutical compositions with antimycotic activity.
The topical application of terbinafine in the treatment of fungal infections, such as mycoses, especially dermatomycoses caused by dermatophytes, e.g. athlete's foot (= tinea pedis), jock itch (= tinea cruris), ringworm or onychomycosis, and dermatomycoses caused by yeasts, e.g. sweat rashes or seborrheic dermatitis, is known in the art. There are now commercially available topical terbinafine products which are able to cure e.g. athlete's foot by just a single administration ("one shot use", Lamisil Once®).
Although the current range of topical terbinafine products available serves most of the patients well, there is still a need for an even better product which combines the excellent antifungal properties of terbinafine with a positive cosmetic effect on the skin area affected by the fungal infection. In particular, with patients suffering from tinea pedis of the moccasin form (= moccasin pedis = plantar tinea pedis), the infected feet are often dry, scaly and thick. In said cases, but not only in those, it would be highly desirable that the topical terbinafine product, in addition to its powerful antifungal action, improved the aspect of an affected foot more rapidly than currently available products. Moreover, a topical terbinafine product that allowed the active substance, terbinafine, more efficiently and rapidly to reach the deepest layer of stratum corneum (where the pathologic fungi usually are located in moccasin pedis) than currently available products would be highly desirable.
In EP 0 273 202 B1 , topical compositions comprising antifungals and hydroxydicarboxylic acids, among them malic acid mentioned, are disclosed which exhibit an enhanced therapeutic activity of the antifungal and which make the antifungal better bioavailable "to the target sites in the skin".
In WO 02/70455, salts of terbinafine with malic acid are disclosed which have beneficial pharmacokinetic and favorable formulation properties.
It has now been found, surprisingly, that by combining (1) a salt of terbinafine with malic acid with (2) certain specific amounts of malic acid in a topical formulation, a topical terbinafine product with the desired profile - powerful antifungal action combined with improved skin- treating properties and a maximized deep penetration of the active substance - is obtained.
The present invention therefore relates to a pharmaceutical composition adapted to topical administration comprising (1) a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition, together with at least one topically acceptable carrier (wt% = weight-%).
Malic acid (2) is HOOC-CH2-CH(OH)-COOH and can be present in racemic or enantiomeric form, preferably in racemic DL(±)- or in enantiomeric L(-)-form, especially in enantiomeric L(-)-form.
Salts of terbinafine with malic acid (1) can either be in hydrogen malate (mono-salt) or malate (di-salt) form, preferred is hydrogen malate. For malic acid incorporated in terbinafine salts (1), the same preferences are valid as indicated for malic acid (2) above. However, there is no requirement to combine e.g. terbinafine DL(±)-hydrogen malate (1 ) always with DL(±)- malic acid (2). Rather, it is very well possible to also combine e.g. terbinafine DL(±)-hydrogen malate (1) with L(-)-malic acid (2) and vice versa.
Typically, the topical pharmaceutical compositions according to the invention comprise the salts of terbinafine with malic acid (1) in an amount of from 0.1 up to 10 wt%, especially of from 0.5 up to 5 wt%, more especially of from 0.5 up to 3 wt% and in particular of from 0.5 up to 1.5 wt%, of the total composition.
Typically, the topical pharmaceutical compositions according to the invention comprise malic acid (2) in an amount of from 0.5 up to 30 wt%, especially of from 0.5 up to 20 wt% and in particular of from 1 up to 10 wt%, of the total composition.
The topically acceptable excipients used largely depend on the kind of topical composition involved (see below). The latter include e.g. aqueous phases, oily phases, emulsions or the typical components of a film-forming solution known per se.
The topical compositions of the invention have valuable pharmacological properties. Especially, they are beneficial in the treatment of infections caused by dermatophytes, such as athlete's foot (tinea pedis), in particular of the moccasin form (moccasin pedis = plantar tinea pedis), jock itch (tinea cruris), ringworm or onychomycosis.
It has surprisingly been found that after administration of the topical compositions of the invention, the skin areas affected by a fungal infection are rapidly and effectively cleared from dry skin residues so that the formation of healthy skin, after defeat of the fungal infection, is facilitated and promoted.
Moreover, the topical compositions of the invention allow better and deeper penetration of the actice substance, terbinafine, to the deep sites where the pathologic fungi are usually located in many dermatomycoses, e.g. in moccasin pedis.
The beneficial properties of the topical compositions of the invention is demonstrated by in vitro, in vivo and clinical tests, for example as follows. In parallel groups of patients suffering from moccasin pedis, compositions of the invention are compared with a commercially available topical antifungal. The dosing and frequency of treatment is the same in both groups. Visual examination within the first two weeks after end of therapy, e.g. after 1 , 2, 3, 5 and 7 days, clearly demonstrates a superiority of the compositions of the invention, what recovery and build-up of healthy skin at the affected skin area is concerned.
Typically, the topically administered pharmaceutical compositions according to the invention comprise the terbinafine salt with malic acid (1) in a pharmacologically effective amount.
The topical pharmaceutical compositions, e.g. in the form of emulsion-gels, gels or creams, may be applied e.g. once, twice or three times daily, but also more frequent daily applications are possible. Film-forming solutions may be applied, for example, once only, or once daily.
The invention further relates to the use of (1 ) a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition (for the manufacture of a pharmaceutical composition adapted to topical administration, which pharmaceutical composition is intended) for the prevention and treatment of fungal infections. Moreover, the invention relates to a method of preventing and treating fungal infections which comprises administering to a mammal in need thereof a topical composition which comprises (1) a therapeutically effective amount of a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition.
Pharmaceutical compositions suitable for topical administration are e.g. emulsion-gels, gels, foam gels, creams, lotions, solutions, microemulsions, ointments, fatty ointments, shampoos, pastes, foams, tinctures, film-forming solutions and nail lacquers (varnishes); preferred are emulsion-gels, gels, foam gels, creams, lotions, solutions, shampoos, film-forming solutions and nail lacquers. The manufacture and composition of such topical pharmaceutical compositions are known in the art (see e.g. WO 98/00168 A1, pages 8-15 or US patent 5,681 ,849). The concept of film-forming solutions is known in the art and e.g. disclosed in WO 98/23291 A1. The concept of nail lacquers (varnishes) is known in the art and e.g. disclosed in EP 515,312 A2.
Preferred are creams (= oil-in-water emulsions), emulsion-gels, gels and film-forming solutions, in particular creams.
The following examples are intended to illustrate the invention.
Example 1: A cream comprising 1.46% terbinafine DL(±)-hydrogen malate and 1.0% DL(±)-malic acid is manufactured as follows.
Inqredients Amount (q/100q)
(A) Terbinafine DL(±)-hydrogen malate (corresponds to
1% terbinafine free base) 1.46
(B) DL(±)-malic acid 1.0
(C) isopropyl myristate 8.0
(D) Polysorbate 60 6.1
(E) sorbitan stearate 1.9
(F) cetyl palmitate 2.0
(G) benzyl alcohol 1.0
(H) stearyl alcohol 4.0
(I) cetyl alcohol 4.0 (J) sodium hydroxide, 30% aqueous solution
(K) water, demineralized ad 100.0
(i) C, D1 E, F, G, H and I are molten together at 75°C.
(ii) A and B are dispersed in K and heated to 75°C.
(iii) The oily phase (i) is added to (ii) and emulsified.
(iv) Optionally (see Examples 2-5), the pH value is adjusted by slowly adding J1 and the cream is cooled.
Example 2: A cream comprising 1.46% terbinafine L(-)-hydrogen malate and
0.5% L(-)-malic acid is manufactured as described in Example 1 , with using 0.5g of L(-)-malic acid (B) and 0.3g of (J).
Example 3: A cream comprising 1.46% terbinafine DL(±)-hydrogen malate and 2.0% DL(±)-malic acid is manufactured as described in Example 1 , with using 2.Og of DL(±)-malic acid (B) and 1.1g of (J).
Example 4: A cream comprising 1.46% terbinafine L(-)-hydrogen malate and
5.0% L(-)-malic acid is manufactured as described in Example 1, with using 5.Og of L(-)-malic acid (B) and 2.5g of (J).
Example 5: A cream comprising 1.46% terbinafine DL(±)-hydrogen malate and
10.0% DL(±)-malic acid is manufactured as described in Example 1, with using 10.0g of
DL(±)-malic acid (B) and 5.1 g of (J).

Claims

Claims
1. A pharmaceutical composition adapted to topical administration comprising (1) a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition, together with at least one topically acceptable excipient.
2. A composition according to claim 1 , wherein the salt of terbinafine with malic acid (1 ) is L(-)-hydrogen malate.
3. A composition according to claim 1 or claim 2, wherein the malic acid (2) is present in an amount of from 0.5 up to 30 wt% of the total composition.
4. A composition according to claim 1 or claim 2, wherein the malic acid (2) is present in an amount of from 1 up to 10 wt% of the total composition.
5. A composition according to any one of claims 1 to 4, wherein the salt of terbinafine with malic acid (1 ) is present in an amount of from 0.5 up to 5 wt% of the total composition.
6. A composition according to any one of claims 1 to 5, which is in the form of an emulsion-gel, a gel, a foam gel, a cream, a lotion or a solution, a shampoo, a film-forming solution or a nail lacquer.
7. Use of (1) a salt of terbinafine with malic acid and (2) malic acid in an amount of from 0.1 up to 50 wt% of the total composition for the manufacture of a pharmaceutical composition adapted to topical administration, which pharmaceutical composition is intended for the prevention and treatment of fungal infections.
PCT/EP2007/002029 2006-03-10 2007-03-08 Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid WO2007104474A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0604934.0 2006-03-10
GB0604934A GB0604934D0 (en) 2006-03-10 2006-03-10 Antifungal compositions
EP06123179 2006-10-30
EP06123179.1 2006-10-30

Publications (1)

Publication Number Publication Date
WO2007104474A1 true WO2007104474A1 (en) 2007-09-20

Family

ID=37919137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002029 WO2007104474A1 (en) 2006-03-10 2007-03-08 Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid

Country Status (1)

Country Link
WO (1) WO2007104474A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105342986A (en) * 2015-11-04 2016-02-24 吉林修正药业新药开发有限公司 Terbinafine hydrochloride gel and preparation method thereof
CN109674757A (en) * 2019-02-22 2019-04-26 济南康和医药科技有限公司 A kind of terbinafine HCl composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273202A2 (en) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
WO2002070455A1 (en) * 2001-02-07 2002-09-12 Novartis Ag Malic acid addition salts of terbinafine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273202A2 (en) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
WO2002070455A1 (en) * 2001-02-07 2002-09-12 Novartis Ag Malic acid addition salts of terbinafine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105342986A (en) * 2015-11-04 2016-02-24 吉林修正药业新药开发有限公司 Terbinafine hydrochloride gel and preparation method thereof
CN109674757A (en) * 2019-02-22 2019-04-26 济南康和医药科技有限公司 A kind of terbinafine HCl composition and preparation method thereof

Similar Documents

Publication Publication Date Title
KR101862448B1 (en) Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
NZ528407A (en) Topical antimycotic compositions comprising terbinafine and diclofenac or indomethacin
KR20190037229A (en) A synergistic antifungal composition and method thereof
US20170071911A1 (en) Pharmaceutical composition for external use
US20110082118A1 (en) Onychomycosis Treatment Delivery System
NZ196042A (en) Anti-acne compositions containing benzoyl peroxide and an azole derivative
WO2007102090A2 (en) Topical formulation
KR20080086515A (en) Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases
EP2431031A2 (en) Composition for preventing hair loss or for stimulating hair growth
CN114206315A (en) Treatment of skin disorders with topical talaroff-EGFR inhibitor compositions
US20210401989A1 (en) Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair
US20030157036A1 (en) Topical dapsone for the treatment of acne
EP2019666B1 (en) Pharmaceutical preparations for transdermal use
WO2008059190A1 (en) Treatment of excess sebum production
JP2007523832A (en) Salicylic acid derivatives and methods as effective enhancers
WO2007104474A1 (en) Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid
KR101733189B1 (en) Composition for promotion of growing nail or toenail
WO2005013955A2 (en) Topical composition comprising terbinafine and hydrocortisone
EP3658160B1 (en) Use of rhamnose derivatives as antifungal agents
RU2431497C1 (en) Co-drug exhibiting antimycotic, antiviral, antimicrobial, anti-inflammatory, immunomodulating and bactericidal action for external or local application
US10273203B2 (en) Deuterated 3-methanesulfonylpropionitrile
JP4499425B2 (en) Transdermal absorption enhancer and athlete's foot treatment composition
US11524016B2 (en) Compositions and methods for the topical administration of spironolactone for the treatment of cutaneous signs of excess androgen and chronic stress response
JP2002507198A (en) Use of cis-6-hexadecenoic acid for the treatment of psoriasis, allergies and autoimmune disorders and for dry and sensitive skin
JP2561684B2 (en) Imidazole derivative, process for its production and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723122

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07723122

Country of ref document: EP

Kind code of ref document: A1